Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 2Tuberous Sclerosis 1Tourette Syndrome 1Tic Disorders 1Pain 1Neurodevelopmental Disorders 1Mental Disorders 1Fragile X Syndrome 1DiGeorge Syndrome 1Depressive Disorder 1Depression 1Caregiver Burden 1Autistic Disorder 1Autism Spectrum Disorder 1Attention Deficit Disorder with Hyperactivity 1Anxiety Disorders 122q11 Deletion Syndrome 1

Interventions

Venlafaxine Hydrochloride 1Specimen Handling 1Selective Serotonin Reuptake Inhibitors 1Psilocybin 1Interviews as Topic 1Dignity Therapy 1Counseling 1Antidepressive Agents, Tricyclic 1Antidepressive Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Depressive Disorder × Selective Serotonin Reuptake Inhibitors × Clear all
NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

Completed
50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡